ompany has entered into distributor agreements with organizations in selected European, Latin American, Middle Eastern, Asian and African countries. Research and Development For the year ended June 30, 2016, the company had research and development expense of $70.6 million. Acquisitions In February 2015, the company completed the acquisition of the Clinic located in Germany approximately 15 miles from its European laboratories in Munich, Germany. Seasonality The company experiences seasonality in its testing business. The volume of testing is negatively impacted by the summer holiday season. The company’s second quarter ending December 31 is generally strong as it sees an increase in volume from patients who have met their annual insurance deductible. Conversely, third quarter ending March 31 is typically negatively impacted by the annual reset of patient deductibles. Patents and Proprietary Rights The company owns or has license rights to various issued patents, as well as patent applications in the United States and foreign countries. It also owns additional patent assets and holds other non-exclusive license rights to patents, which cover various aspects of its tests or processes. Vectra DA-The company holds an exclusive license to one issued U.S. patent and pending U.S. patent applications relating to VectraDA testing. This issued U.S. patent has a term expected to expire in 2031 and these U.S. applications, if issued as patents and depending on term adjustments or terminal disclaimers if applicable, are expected to have similar terms. Prolaris-The company owns or holds an exclusive license to one allowed U.S. patent application and pending U.S. patent applications relating to Prolaris testing. This allowed U.S. patent application, if and when issued, would have a term expected to expire in 2031 and these U.S. applications, if issued as patents and depending on term adjustments or terminal disclaimers if applicable, are expected to have expiration timeframes ranging from 2030 to 2035. EndoPredict-The company owns or holds an exclusive license to two issued European patents and pending U.S. and European patent applications relating to EndoPredict testing. These issued European patents have a term expected to expire in 2031 and these U.S. and European applications, if issued as patents and depending on term adjustments or terminal disclaimers if applicable, are expected to have similar expiration timeframes. myChoice HRD-The company owns or holds an exclusive license to two issued U.S. patents and pending U.S. patent applications relating to myChoice HRD testing. These issued U.S. patents have terms expected to expire in 2032 and these U.S. applications, if issued as patents and depending on term adjustments or terminal disclaimers if applicable, are expected to have expiration timeframes ranging from 2031 to 2035. Trademarks Myriad, BRACAnalysis, BRACAnalysis CDx, BART, COLARIS, COLARIS AP, MELARIS, myPath, myPlan, myChoice, myRisk, Myriad myRisk, PANEXIA, PREZEON, Prolaris, myChoice HRD, Vectra, Vectraview, TruCulture, DiscoveryMAP, RodentMap and EndoPredict are registered trademarks or trademarks of the company. Governmental Regulation Each of the company’s clinical laboratories must hold certain federal, state and local licenses, certifications and permits to conduct its business. Laboratories in the United States that perform testing on human specimens for the purpose of providing information for the diagnosis, prevention, or treatment of disease are subject to the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Its laboratories in Salt Lake City, Utah, Austin, Texas and South San Francisco, California are CLIA certified to perform high complexity tests. As the company’s laboratories are accredited by the College of American Pathologists (CAP), which is a CMS-approved accreditation organization, they are typically subject to CAP inspections. The company is subject to the Health Insurance Portability and Accountability Act of 1996 (HIPAA) regulations and maintains an active compliance program that is designed to identify security incidents and other is
myriad genetics inc
(MYGN:Consolidated Issue Listed on NASDAQ Global Select )
320 Wakara Way
Salt Lake City, UT 84108
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for MYGN.|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.